A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer

doi:10.1007/s00259-022-05701-3

	A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer
	Shang, Wenting1 ; Peng, Li 2,3; He, Kunshan1,4 ; Guo, Pengyu 2,3; Deng, Han 1; Liu, Yu 4; Chen, Ziyin 2,3; Tian, Jie 1,4; Xu, Wanhai 2,3
发表期刊	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
ISSN	1619-7070
	2022-02-21
页码	13
通讯作者	Tian, Jie(jie.tian@ia.ac.cn) ; Xu, Wanhai(xuwanhai@163.com)
摘要	Background Bladder cancer is the fifth most common malignancy in humans. Cystoscopy under white light imaging is the gold standard for bladder cancer diagnosis, but some tumors are difficult to visualize and can be overlooked, resulting in high recurrence rates. We previously developed a phage display-derived peptide-based near-infrared imaging probe, PLSWT7-DMI, which binds specifically to bladder cancer cells and is nontoxic to animals. Here, we report a clinical research of this probe for near-infrared fluorescence endoscopic detection of bladder cancer. Results The purity, efficacy, safety, and nontoxicity of PLSWT7-DMI were confirmed prior to its clinical application. Twenty-two patients diagnosed with suspected non-muscle invasive bladder cancer were enrolled in the present study. Following intravesical administration of the probe, the entire mucosa was imaged under white and near-infrared imaging using an in-house developed endoscope that could switch between these two modes. The illuminated lesions under near-infrared light were biopsied and sent for histopathological examination. We observed a 5.1-fold increase in the fluorescence intensity in the tumor samples compared to normal tissue, and the probe demonstrated a sensitivity and specificity of 91.2% and 90%, respectively. Common diagnostic challenges, such as small satellite tumors, carcinoma in situ, and benign suspicious mucosa, were visualized and could be distinguished from cancer. Furthermore, no adverse effects were observed in humans. These first-in-human results indicate that PLSWT7-DMI-based near-infrared fluorescence endoscopy is a safe and effective approach for the improved detection of bladder cancer, and may enable thorough resection to prevent recurrence.
关键词	Bladder cancer Near-infrared imaging Peptide Diagnosis Endoscopy
DOI	10.1007/s00259-022-05701-3
关键词[WOS]	CARCINOMA IN-SITU ; TRANSURETHRAL RESECTION ; PHOTODYNAMIC DIAGNOSIS ; LIGHT CYSTOSCOPY ; WHITE-LIGHT ; RECURRENCE ; THERAPY
收录类别	SCI
语种	英语
WOS研究方向	Radiology, Nuclear Medicine & Medical Imaging
WOS类目	Radiology, Nuclear Medicine & Medical Imaging
WOS记录号	WOS:000758972300001
出版者	SPRINGER
七大方向——子方向分类	医学影像处理与分析
引用统计	被引频次：4[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/47883
专题	中国科学院分子影像重点实验室
通讯作者	Tian, Jie; Xu, Wanhai
作者单位	1.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing Key Lab Mol Imaging,State Key Lab Managem, Beijing 100190, Peoples R China 2.Harbin Med Univ, Urol Surg Dept, Hosp 4, Harbin 150001, Heilongjiang, Peoples R China 3.NHC Key Lab Mol Probes & Targeted Diag & Therapy, Yiyuan St 37, Harbin 150001, Heilongjiang, Peoples R China 4.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med & Engn, Zhongguancun East Rd 95, Beijing 100191, Peoples R China
第一作者单位	中国科学院自动化研究所
通讯作者单位	中国科学院自动化研究所
推荐引用方式 GB/T 7714	Shang, Wenting,Peng, Li,He, Kunshan,et al. A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,2022:13.
APA	Shang, Wenting.,Peng, Li.,He, Kunshan.,Guo, Pengyu.,Deng, Han.,...&Xu, Wanhai.(2022).A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,13.
MLA	Shang, Wenting,et al."A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer".EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022):13.